Back to top

Surging Earnings Estimates Signal Good News for ANI Pharmaceuticals (ANIP)
February 25, 2014

Read MoreHide Full Article
ANI Pharmaceuticals, Inc. (ANIP - Free Report) , engaged in developing, manufacturing and marketing of generic and branded drugs, could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.

These positive earnings estimate revisions suggest that analysts are becoming more optimistic on ANIP’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames, suggesting that ANI Pharmaceuticals could be a solid choice for investors.

Current Quarter Estimates for ANIP

In the past 30 days, 2 estimates have gone higher for ANI Pharmaceuticals with no downward revision. The consensus estimate trend has been pretty favorable, with estimates increasing from 27 cents per share 30 days ago to 37 cents today, a move of 37.0%.

Current Year Estimates for ANIP

Meanwhile, ANI Pharmaceuticals’ current year figures are also looking quite promising with 2 estimates moving higher in the past month. The consensus estimate trend has also seen a boost for this time frame, increasing from 98 cents per share 30 days ago to $1.35 today , a move of 37.8%.

Bottom Line

The stock has also started to move higher lately, adding 25.5% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #3 (Hold) stock to profit in the near future.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

ANI Pharmaceuticals, Inc. (ANIP) - free report >>

More from Zacks Tale of the Tape

You May Like